Adimab vs Summation Bio, Inc.
Adimab vs Summation Bio, Inc., compared side by side on 14 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Adimab is on 53/100 and Summation Bio, Inc. on 41/100.
Where each one leads
Adimab
- our overall score: 53/100 against 41/100
- agent readiness: 40/100 against 22/100
- funding raised: $105M against $10.0M
Summation Bio, Inc.
Leads on none of the measures we hold for both companies.
At a glance
| Measure | Adimab | Summation Bio, Inc. |
|---|---|---|
| What it is | Adimab is a biotechnology company that discovers and develops therapeutic antibodies using its proprietary yeast-based platform. | Biotechnology company |
| Category | Biotech, Drug Discovery, Antibody Discovery, Therapeutic Antibodies | Biotech, Drug Discovery, Genomics, HealthTech |
| Sells toBusiness model | B2B | B2B |
| Offering | Platform | Services |
| Founded | 2007 | 2021 |
| Headquarters | Lebanon, United States | Cambridge, United States |
| Status | Active | Inactive |
Size, funding and growth
| Measure | Adimab | Summation Bio, Inc. |
|---|---|---|
| Employees | 139 | Not published |
| Total funding | $105M | $10.0M |
| Latest round | Series B | Seed |
| LinkedIn followers | 8,423 | Not published |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Adimab | Summation Bio, Inc. |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 53/100 | 41/100 |
| Traction | 60/100 | 35/100 |
| Team | Not published | 60/100 |
| Community | Not published | 15/100 |
| Search visibility | 20/100 | 15/100 |
| Quality | 68/100 | 45/100 |
| Agent readinessHow well an AI agent can read and act on the site | D (40/100) | F (22/100) |
| Domain ratingLink authority, 0-100 | 39/100 | Not published |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Adimab | Summation Bio, Inc. |
|---|---|---|
| Hosting | AWS | Not detected |
| CMS | WordPress | Not detected |
| Frameworks | Jquery, Bootstrap | Not detected |
| Analytics | Google Tag Manager, Linkedin Insight | Not detected |
| Support stack | HubSpot | Not detected |
Adimab vs Summation Bio, Inc.: common questions
Which is better, Adimab or Summation Bio, Inc.?
On our 0-100 score Adimab rates higher (53/100 against 41/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 14 data points above: read the rows that match what you are buying for.
How do Adimab and Summation Bio, Inc. compare on the numbers?
Adimab leads on our overall score (53/100 against 41/100), agent readiness (40/100 against 22/100), funding raised ($105M against $10.0M).
Read the full Adimab review and pricing or the Summation Bio, Inc. review and pricing. You can also browse other Adimab alternatives we track.